✅ Stock in Focus: Max Healthcare Institute Ltd. (MAXHEALTH)

🏥 Why Max Healthcare Will Benefit the Most Among all listed hospital chains, Max Healthcare is set to gain the most from the government’s recent CGHS rate revision — the first major hike in over a decade. The move raises reimbursement rates by 5–30% across key procedures and differentiates hospitals based on accreditation and scale. Max Healthcare’s strong presence in Delhi-NCR — the largest CGHS market — combined with full NABH accreditation and a large share of government-insured patients gives it a direct earnings tailwind. Analysts estimate an 18–22% jump in EBITDA over the next few quarters as revised rates flow through and patient volumes rise. 📈 Analyst & Concall Highlights Brokerages such as Emkay Global and Nuvama have already upgraded earnings expectations for Max Healthcare, citing improved realisations and better cashflow cycles. Management commentary indicates that higher reimbursements and faster collections will support both margin expansion and sustained patient inflow without a proportional rise in costs. Institutional investors also see this as a structural re-rating trigger, not just a short-term boost. 🚀 Sector View The CGHS overhaul has reignited optimism in the hospital and healthcare space, but the benefit will not be uniform. Smaller or non-accredited hospitals may see limited upside due to lower reimbursement slabs. Large, accredited players like Max Healthcare are positioned to capture the full benefit of this reform. In short — Max Healthcare emerges as the clearest winner of the CGHS revision, thanks to its scale, operational leverage, and strategic exposure to government-linked health schemes. The policy shift strengthens its earnings visibility and long-term growth story.